Zosano Pharma Corporation
34790 Ardentech Court
Fremont
California
94555
United States
Tel: 510-745-1200
128 articles about Zosano Pharma Corporation
-
Zosano Pharma Announces Completion of Pre-NDA Meetings with FDA for Qtrypta™Zosano plans to submit NDA for Qtrypta in December 2019
11/13/2019
Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced that it has received minutes from pre- New Drug Application meetings with the Food and Drug Administration for the acute treatment of migraine for Qtrypta.
-
Zosano Pharma to Host Conference Call on Third Quarter 2019 Financial Results and Provide Operational Update
11/7/2019
The Company will announce its financial results for this period in a press release to be issued prior to the call.
-
Zosano Pharma Initiates Phase 2/3 Clinical Study in Cluster HeadacheAdvances Second Late Stage Program for ADAM Microneedle Technology
10/24/2019
Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced that the company has begun enrolling cluster headache patients in the ATAC clinical trial.
-
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/23/2019
The stock option has an exercise price of $1.94 per share, which is equal to the closing price of Zosano’s common stock on the grant date, October 21, 2019.
-
Clinical Catch-Up: September 9-13
9/16/2019
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories. -
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results
3/14/2019
Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2018, as well as recent business highlights.
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
Zosano Pharma Engages Contract Manufacturer as Part of the Commercialization Strategy for M207
10/3/2018
Zosano Pharma Corporation today announced a manufacturing and supply agreement for M207 with a leading global contract development and manufacturing organization, which serves more than 400 clients in the pharmaceutical and biotechnology sectors.
-
Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split
1/25/2018
The Company will effect a reverse stock split of its issued and outstanding common stock at an exchange ratio of 1-for-20, at 5:00 p.m. Eastern Time on Thursday, January 25, 2018
-
Zosano Pharma Announces Notice of Allowance for a U.S. Patent Application Covering M207 as an Acute Treatment for Migraine
1/3/2018
Issuance will extend patent life of M207 to 2037.
-
Zosano Announces Resignation of Bruce Steel from Board of Directors
12/18/2017
Following up on Mr. Steel's resignation, the number of Board of Director seats has been reduced to five.
-
Zosano Pharma Reports Third Quarter 2017 Financial Results and Operational Update
11/10/2017
Zosano reported a net loss for the third quarter of 2017 of $7.9 million.
-
Zosano Pharma Announces Initiation of Long-Term Safety Study for M207 as an Acute Treatment of Migraine
11/8/2017
M207-ADAM is an open label study evaluating the safety of the 3.8mg dose of zolmitriptan in migraine patients who have historically experienced at least 2 migraines per month.
-
Zosano Pharma to Host Conference Call on Third Quarter 2017 Financial Results and Provide Operational Update
11/1/2017
The Company will announce its financial results for this period in a press release to be issued prior to the call.
-
Zosano Announces Publication Of Pivotal Data Of ADAM Zolmitriptan For The Acute Treatment Of Migraine In Cephalalgia
10/13/2017
-
Zosano Appoints Kenneth Greathouse To Board Of Directors
10/4/2017
-
Zosano Provides Patent Application Update
9/27/2017
-
Zosano Announces U.S. Patent Office Publication Of “Method Of Rapidly Achieving Therapeutic Concentrations Of Triptans For Treatment Of Migraines”
8/28/2017
-
Zosano Reports Second Quarter 2017 Financial Results And Operational Update
8/11/2017
-
Zosano To Host Conference Call On Second Quarter 2017 Financial Results And Provide Operational Update
8/2/2017